AngioDynamics, Inc. to Post Q4 2024 Earnings of ($0.21) Per Share, HC Wainwright Forecasts (NASDAQ:ANGO)

AngioDynamics, Inc. (NASDAQ:ANGO) – HC Wainwright decreased their Q4 2024 earnings per share (EPS) estimates for shares of AngioDynamics in a research report issued to clients and investors on Wednesday, May 22nd. HC Wainwright analyst Y. Chen now anticipates that the medical instruments supplier will earn ($0.21) per share for the quarter, down from their prior forecast of ($0.20). HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for AngioDynamics’ Q2 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.68) EPS.

Separately, Oppenheimer upgraded AngioDynamics from a “market perform” rating to an “outperform” rating and set a $12.00 target price on the stock in a report on Friday, April 5th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $13.25.

AngioDynamics Price Performance

AngioDynamics stock opened at $6.17 on Friday. The company has a market cap of $247.17 million, a price-to-earnings ratio of -1.27 and a beta of 0.67. The firm has a 50-day moving average of $6.07 and a 200-day moving average of $6.33. AngioDynamics has a one year low of $5.26 and a one year high of $11.38.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, April 4th. The medical instruments supplier reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). AngioDynamics had a negative return on equity of 3.48% and a negative net margin of 60.21%.

Insider Activity

In other AngioDynamics news, CEO James C. Clemmer purchased 10,000 shares of the stock in a transaction on Monday, April 8th. The shares were purchased at an average price of $6.70 per share, with a total value of $67,000.00. Following the completion of the transaction, the chief executive officer now directly owns 539,066 shares in the company, valued at $3,611,742.20. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On AngioDynamics

Institutional investors and hedge funds have recently modified their holdings of the stock. Armistice Capital LLC bought a new position in shares of AngioDynamics during the fourth quarter worth approximately $6,272,000. Fund 1 Investments LLC bought a new stake in shares of AngioDynamics in the fourth quarter valued at about $3,896,000. Assenagon Asset Management S.A. grew its stake in shares of AngioDynamics by 85.7% in the third quarter. Assenagon Asset Management S.A. now owns 1,054,022 shares of the medical instruments supplier’s stock valued at $7,705,000 after acquiring an additional 486,501 shares in the last quarter. Western Standard LLC increased its position in AngioDynamics by 878.5% during the first quarter. Western Standard LLC now owns 523,393 shares of the medical instruments supplier’s stock worth $3,072,000 after acquiring an additional 469,906 shares during the period. Finally, Acadian Asset Management LLC bought a new stake in AngioDynamics in the 3rd quarter valued at about $2,630,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

About AngioDynamics

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.